(Q42437883)

English

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells

scientific article published on 29 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 October 2017

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells (English)

1 reference

Europe PubMed Central

31 October 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Raffaele De Palma

17

1 reference

Europe PubMed Central

31 October 2017

12

object named as

Sabine Tejpar

0 references

Fortunato Ciardiello

18

object named as

Fortunato Ciardiello

1 reference

Europe PubMed Central

31 October 2017

Liberato Berrino

16

object named as

Liberato Berrino

1 reference

Europe PubMed Central

31 October 2017

author name string

Erika Martinelli

1

1 reference

Europe PubMed Central

31 October 2017

Teresa Troiani

2

1 reference

Europe PubMed Central

31 October 2017

Elena D'Aiuto

3

1 reference

Europe PubMed Central

31 October 2017

Floriana Morgillo

4

1 reference

Europe PubMed Central

31 October 2017

Donata Vitagliano

5

1 reference

Europe PubMed Central

31 October 2017

Anna Capasso

6

1 reference

Europe PubMed Central

31 October 2017

Sarah Costantino

7

1 reference

Europe PubMed Central

31 October 2017

Loreta Pia Ciuffreda

8

1 reference

Europe PubMed Central

31 October 2017

Francesco Merolla

9

1 reference

Europe PubMed Central

31 October 2017

Loredana Vecchione

10

1 reference

Europe PubMed Central

31 October 2017

Veerle De Vriendt

11

1 reference

Europe PubMed Central

31 October 2017

Anna Nappi

13

1 reference

Europe PubMed Central

31 October 2017

Vincenzo Sforza

14

1 reference

Europe PubMed Central

31 October 2017

Giulia Martini

15

1 reference

Europe PubMed Central

31 October 2017

language of work or name

0 references

publication date

29 May 2013

1 reference

Europe PubMed Central

31 October 2017

number of pages

13

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

31 October 2017

133

1 reference

Europe PubMed Central

31 October 2017

9

1 reference

Europe PubMed Central

31 October 2017

2089-2101

1 reference

Europe PubMed Central

31 October 2017

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Targeting the PI3K signaling pathway in cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Therapeutic potential of phosphoinositide 3-kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

PI3K pathway alterations in cancer: variations on a theme

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

RAS Interaction with PI3K: More Than Just Another Effector Pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Targeting RAS signalling pathways in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Ras, PI(3)K and mTOR signalling controls tumour cell growth

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

The phosphoinositide 3-kinase pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

CLCP1 interacts with semaphorin 4B and regulates motility of lung cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Targeting PI3K/mTOR signaling in cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

WWP2 is an E3 ubiquitin ligase for PTEN.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28236

21 January 2018

Identifiers

10.1002/IJC.28236

1 reference

Europe PubMed Central

31 October 2017

1 reference

Europe PubMed Central

31 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42437883&oldid=1944934255"